Welcome to our dedicated page for OCULAR THERAPEUTIX SEC filings (Ticker: OCUL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on OCULAR THERAPEUTIX's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into OCULAR THERAPEUTIX's regulatory disclosures and financial reporting.
OCUL affiliate filed a Form 144 proposing the sale of 3,018 shares of Common Stock. The transaction is described as restricted stock vesting under a registered plan with a proposed sale date of 05/22/2026 and the Form 144 filing dated 05/26/2026.
The filing reports a Rule 144 notice for 21,156 shares of Common Stock associated with restricted stock vesting under a registered plan. The notice lists the transaction date as 05/22/2026 and identifies the filer as Morgan Stanley Smith Barney LLC.
This form records the planned sale under Rule 144; no proceeds, price, or purchaser details are included in the provided excerpt.
Ocular Therapeutix, Inc. ownership update: Deep Track reports beneficial ownership of 20,850,000 shares of Common Stock, equal to 9.53% of the class as of March 31, 2026. The filing states the amount is calculated using 218,855,497 shares (based on 217,691,779 shares outstanding as of February 2, 2026) and includes 1,163,718 Pre-Funded Warrants exercisable to common shares, subject to a 9.99% Maximum Percentage exercise limitation.
The filing is a joint Schedule 13G/A by Deep Track Capital, LP; Deep Track Biotechnology Master Fund, Ltd.; and David Kroin, who is identified as a control person for Deep Track Capital, LP. It specifies that Deep Track Capital, LP is the relevant entity through which the position is held.
Ocular Therapeutix reported a larger quarterly loss while advancing its lead retina drug AXPAXLI through late-stage trials. For the first quarter ended March 31, 2026, total net revenue was $10.8 million, up slightly from $10.7 million a year earlier, driven almost entirely by DEXTENZA product sales.
Research and development spending rose to $66.2 million from $42.9 million as the company funded its Phase 3 SOL-1, SOL-R and HELIOS-3 trials and initiated the SOL-X extension study. Net loss widened to $88.6 million, or $0.40 per share, compared with a $64.1 million loss, or $0.38 per share, in the prior-year quarter.
Cash and cash equivalents were $666.7 million as of March 31, 2026. Ocular believes this balance can fund planned expenses, debt service and capital needs into 2028, including completion of SOL-1, SOL-R topline data, SOL-X, HELIOS-3 and potential HELIOS-2, as well as pre-commercial investment for AXPAXLI.
Ocular Therapeutix is asking stockholders to approve several 2026 annual meeting items, including electing two Class III directors, advisory votes on executive pay and its frequency, and a proposal to increase the 2021 Stock Incentive Plan share pool by 10,000,000 shares.
The proxy highlights 2025 as a transformative year, with expanded Phase 3 programs for AXPAXLI in wet age-related macular degeneration and diabetic retinal disease, a special protocol assessment from the FDA, and $475 million in gross proceeds from an underwritten offering. The company reports sufficient capital, together with anticipated DEXTENZA cash inflows, to fund planned operations, debt service and capital spending into 2028, and notes positive superiority data from the SOL‑1 Phase 3 trial in wet AMD. The board emphasizes a pay-for-performance executive compensation philosophy, heavy use of at-risk equity, independent board oversight, and ongoing stockholder engagement, including outreach to investors holding 31% of shares outstanding after a 74.9% say‑on‑pay support level in 2025.
Ocular Therapeutix director Pravin Dugel reported a bona fide gift of 394,696 shares of Common Stock on April 9, 2026, transferred to his spouse for no consideration. The transfer was recorded as a gift disposition and reflects an internal family reallocation rather than a market sale.
After this transaction, Dugel continues to hold 2,618,326 shares directly. He also has indirect ownership of 394,696 shares held by his spouse and 300,115 shares held by the Pravin Dugel 2024 Irrevocable Trust, indicating a substantial remaining stake in the company.
Ocular Therapeutix Inc: The Vanguard Group filed Amendment No. 2 to a Schedule 13G/A reporting 0 shares beneficially owned, representing 0% of the class. The amendment explains an internal realignment on January 12, 2026 that led subsidiaries to report holdings separately; Ashley Grim signed on 03/27/2026.
Ocular Therapeutix, Inc. is making investor presentation slides available covering detailed results from its SOL-1 Phase 3 superiority clinical trial of AXPAXLI (also known as OTX-TKI) for treating wet age-related macular degeneration. The slides will be posted on the company’s website Investors section on February 27, 2026, aligned with its presentation at the 49th Macula Society Annual Meeting.